Fig 5.

Cisplatin-induced death of prostate cancer cells can be prevented by silencing EndoG. (A) EndoG-positive 22Rv1 cells treated with DY547-labeled anti-EndoG siRNA had EndoG expression and DNA fragmentation (TUNEL) significantly decreased compared to the cells treated with transfection reagent only (“non-treated”) or with non-specific control siRNA, and were protected from cell death induced by cisplatin (80 μM) exposure for 24 h. n=4 per group, *p<0.05 compared to non-treated or cells treated with control siRNA. (B) Representative images of the cells after treatment with cisplatin. Bar, 10 μm. (C) Silencing of EndoG in 22Rv1 cells by anti-EndoG siRNA caused increased viability of the cells during exposure with cisplatin (2.5–10 μM) (n=4 per group, *p<0.01 to non-treated or cells treated with control siRNA).